Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CVAC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CVAC

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

CureVac NV

CVAC
Current price
5.41 USD -0.05 USD (-0.92%)
Last closed 5.46 USD
ISIN NL0015436031
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 227 116 544 USD
Yield for 12 month +51.97 %
1Y
3Y
5Y
10Y
15Y
CVAC
21.11.2021 - 28.11.2021

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. Address: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.30 USD

P/E Ratio

5.80

Dividend Yield

Financials CVAC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CVAC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+625 566 181 USD

Last Year

+62 837 152 USD

Current Quarter

+1 043 818 USD

Last Quarter

+16 912 659 USD

Current Year

+501 863 794 USD

Last Year

-82 532 936 USD

Current Quarter

+21 040 USD

Last Quarter

+15 175 690 USD
EBITDA 240 862 000 USD
Operating Margin TTM -6 128.33 %
Price to Earnings 5.80
Return On Assets TTM 19.93 %
PEG Ratio
Return On Equity TTM 33.04 %
Wall Street Target Price 4.30 USD
Revenue TTM 523 700 000 USD
Book Value 2.87 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -92.80 %
Dividend Yield
Gross Profit TTM 458 884 000 USD
Earnings per share 0.94 USD
Diluted Eps TTM 0.94 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin 34.50 %

Stock Valuation CVAC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 5.80
Forward PE 5.24
Enterprise Value Revenue 1.24
Price Sales TTM 2.34
Enterprise Value EBITDA 2.86
Price Book MRQ 1.63

Technical Indicators CVAC

For 52 Weeks

2.37 USD 5.72 USD
50 Day MA 4.52 USD
Shares Short Prior Month 2 602 326
200 Day MA 3.49 USD
Short Ratio 1.37
Shares Short 891 128
Short Percent 2.31 %